Navigation Links
Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions

n via a single insertion of ITCA 650.

    Fasting & Postprandial Glucose             ITCA 650 Dose Arms
                                             (continuous daily dose)
                                       10        20        40        80
                                     mcg/day   mcg/day   mcg/day   mcg/day
    Mean FPG at baseline (mg/dL)      161.2     170.5     171.8     145.1
    Mean FPG at end of treatment
     (mg/dL)                          155.6     139.4     129.8     116.3
    Change from baseline (mg/dL)       -5.6     -31.1     -42.0     -28.8
    Change in 2-hr PPG at end of
     treatment (mg/dL)                 -8.8     -32.3     -47.1     -74.6

Substantial decreases in FPG and PPG were observed throughout treatment. Decreases in FPG were evident within 24 hours of the initiation of treatment suggesting a rapid and consistent achievement of desired exenatide levels with DUROS delivery. Changes in PPG measured at days 15 and 29 also showed consistent dose-dependent reductions.

    HbA1c & Body Weight                        ITCA 650 Dose Arms
                                             (continuous daily dose)
                                       10        20        40        80
                                     mcg/day   mcg/day   mcg/day   mcg/day
    % HbA1c at baseline               7.67      7.90      7.45      7.38
    % HbA1c at end of treatment       7.15      7.28      7.00      6.80
    Change from baseline             -0.52     -0.62     -0.45     -0.58
    Mean change in weight (kg)       -0.28     -0.31     -0.93     -2.91

Although the treatment duration in the study was only 28 days, decreases in HbA1c and body weight were observed across all dose arms. The most commonly reported adverse events were nausea and vomiting which were mostly mild, transient and dose dependent.

"The results

SOURCE Intarcia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
2. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
3. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
4. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
5. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
6. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
7. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
8. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
9. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
10. Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
11. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
Post Your Comments:
(Date:1/14/2014)... 2014 EquitiesIQ, a leading informational ... (OTCQB: ALQA). Alliqua is an emerging biomedical company ... serve the wound care market. , Free report ... Alliqua was restructured with a seasoned management team ... to become a leading provider of wound care ...
(Date:1/14/2014)... January 14, 2014 iLab Solutions, the ... Detwiler as the new Director of Product Strategy. In ... clients as well as iLab sub-teams to guide in ... be to ensure that iLab provides the maximum possible ... advanced, user-friendly, and high-impact solution in the world. ...
(Date:1/14/2014)... 14, 2014 Global Record Systems, ... information technology solutions for patients, physicians, the biopharmaceutical ... announced today the signing of a three-year Research ... Drug Administration (FDA). This initiative is designed ... patient safety, clinical outcomes, and medication adherence. , ...
(Date:1/14/2014)... 14, 2014 Kerr Corporation, a leading manufacturer ... additional how-to information about dual arch impressions on its dental ... Arch Impressions,” the blog entry serves up a list of ... a step-by-step demonstration by Dr. David Little as he crafts ... Take 1 Advanced Rigid as the dual arch dental ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... May 21 The American Acne & Rosacea Society ... Month which will occur in June 2009. At the ... Rosso, DO, President, stated that National Acne Awareness Month ... the treatment of acne and to generate awareness for ...
... Inc. ("Sinobiopharma ", or "the Company") (OTC Bulletin ... has applied for two Chinese patents for its ... relaxant. The Company has applied to China,s State ... for Atracurium,s freeze-drying compounds (Application Number 200710127756.2; "Atracurium,s ...
... 20 InspireMD, Ltd. announced today,the completion of ... The trial was designed to confirm the clinical ... Primary PCI in STEMI,patients. , ... single arm, 60 patients,study (Principal investigator: Dr. Dariusz ...
Cached Biology Technology:American Acne & Rosacea Society Announces Acne Awareness Month - June 2009 2Sinobiopharma Applies For Two Chinese Patents For Cisatracurium Besylate 2InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR '09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le 2InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR '09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le 3
(Date:4/15/2014)... San Diego have succeeded in visualizing the movement ... growth and resistance to drought. The achievement will ... how the hormone helps plants respond to drought ... increase in the atmosphere,s carbon dioxide, or CO2, ... the April 15 issue of the scientific journal ...
(Date:4/15/2014)... of the loveliest in the world, but they also ... soils have become enriched in cadmium. Grasses take up ... the cattle and sheep that graze them. The problem ... reported worldwide. , The concern is that if cadmium ... products, human health and New Zealand,s agricultural economy could ...
(Date:4/15/2014)... the Congo Basin to increase by 0.7 C. ... gases by half, according to a study by ... Explosive population growth and inefficient agricultural practices are ... Africa. A team of researchers from the University ... longer-term temperatures in the region. Using a sophisticated ...
Breaking Biology News(10 mins):Biologists develop nanosensors to visualize movements and distribution of plant hormone 2Study: Deforestation could intensify climate change in Congo Basin by half 2
... ways in which cooperation is the theme of a paper ... scientists at the Marine Biological Laboratorys (MBL) Josephine Bay Paul ... where the Alliegros thank those who helped them after Hurricane ... in New Orleans and their lives in 2005. ...
... sophisticated unmanned aircraft, research scientists at Scripps Institution ... Southern Californias potential for climate change and better ... by the California Energy Commission, the California AUAV ... aerial vehicles (AUAVs) to gather meteorological data as ...
... a protein in the blood linked to defence ... previously understood in the bodys immune defence system. ... of how the body defends against disease and heals ... protein, Properdin discovered only half a century ago- can ...
Cached Biology News:The cooperative view: New evidence suggests a symbiogenetic origin for the centrosome 2Unmanned aircraft to study Southern California smog and its consequences 2Unmanned aircraft to study Southern California smog and its consequences 3New discovery on role of vital protein that fights meningitis 2
... is the industry standard microarray image analysis ... imaging and analysis tools, visualizations, automation capabilities, ... is included with every GenePix scanner, and ... scanners and all types of arrays. A ...
... one mouse-click image analysis software for ... is the solution for high quality ... MicroVigene is empowered with VigeneTechs robust ... regional 2D-curve fitting background correction and ...
... applications not requiring confocal, the BD Pathway ... the Pathway 435. And, the Pathway 415 ... applications require it. High-performance, ... to use the laser autofocus, camera autofocus, ...
... ProXPRESS 2D Proteomic Imaging System, Professional ... Over a Wide Dynamic Range: The ProXPRESS ... sensitive in imaging system for both proteomic ... 2D provides unparalleled flexibility, enabling the use ...
Biology Products: